Citius Oncology (CTOR) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Citius Oncology (CTOR) over the past year, losing 32.1% versus a loss of 54.6%. Citius Oncology is the larger company by market cap ($88.8 million vs $40.6 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | SCYX |
|---|---|---|
| Share price | $0.8398 | $4.08 |
| Market cap | $88.82M | $40.59M |
| 1-day change | +0.57% | -3.32% |
| YTD return | -16.50% | -16.53% |
| 1-year return | -54.62% | -32.11% |
| 5-year return | — | -90.53% |
| EPS (TTM) | $-0.48 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $9.12 |
| 52-week low | $0.491 | $3.53 |
| Distance from 52-week high | -62.68% | -55.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +376.30% | +790.44% |
| Average volume | 100.32K | 279.10K |
| Shares outstanding | 105.76M | 9.95M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Citius Oncology is about 2.2 times larger than SCYNEXIS by market value ($88.82M vs $40.59M).
- SCYX has outperformed CTOR by 22.5 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
CTOR vs SCYX FAQ
Which is bigger, Citius Oncology or SCYNEXIS?
Citius Oncology (CTOR) is larger, with a market capitalization of $88.82M compared with $40.59M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, CTOR or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.